• Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells

  2026-10-06

  The reference study introduces a macrophage phenotypic screening strategy to identify small molecules that lower SPP1 expression, rather than relying on broad in vitro polarization labels. Its lead compound, CANDI460, was incorporated into a TAM-avid nanocarrier and reduced SPP1 in cellular and murine tumor models, supporting a targeted approach to tumor microenvironment macrophage modulation while leaving important translational questions unresolved.

• LGK-974 and Wnt Signaling: Evidence and Limits

  2026-10-06

  LGK-974 is a research compound designed to inhibit PORCN, an enzyme required for the secretion of many Wnt ligands. This overview distinguishes supplier-reported pharmacology and cancer-model observations from peer-reviewed developmental biology, including a 2025 study of Wnt and BMP patterning in the hemichordate Ptychodera flava. It also examines evidence strength, model-specific interpretation, biomarker questions, and the limits of extrapolating between embryonic patterning, cell assays, and oncology.

• Fucoidan in Cancer Research: Evidence and Limitations

  2026-10-05

  A source-grounded overview of Fucoidan as a sulfated α-L-fucan, covering its proposed anticancer mechanisms, recent MCF-7 breast cancer findings, evidence from prostate and animal models, and the limitations that constrain translational interpretation.

• Lenalidomide and DOT1L: A Translational Myeloma Lens

  2026-10-05

  A source-grounded analysis of how Lenalidomide and DOT1L inhibition intersect in multiple myeloma research, with emphasis on mechanism, evidence strength, translational boundaries, and future biomarker strategy.

• Schwartz on In Vitro Cancer Drug Response Metrics

  2026-10-04

  Hannah Schwartz’s 2022 doctoral dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for separating proliferative arrest from cell death while accounting for their differing proportions and timing, improving interpretation of in vitro cancer studies.

• Machine Learning Discovery of Senolytics

  2026-10-03

  A Nature Communications study used machine learning trained on published data to prioritize senolytic candidates and identified ginkgetin, periplocin, and oleandrin for validation in human cell models. The work demonstrates how computational prioritization can extract value from small, heterogeneous datasets while leaving important questions about selectivity, mechanism, safety, and clinical translation unresolved.

• Ridaforolimus: Practical mTOR Assay Guide

  2026-10-02

  A scenario-based guide to using Ridaforolimus (Deforolimus, MK-8669), SKU B1639, in viability, proliferation, angiogenesis, and senescence-related experiments. It covers solvent handling, dose selection, pathway controls, interpretation limits, and practical supplier comparison.

• RNA G-Quadruplexes Shape TDP-43 Condensation

  2026-10-01

  Oldani et al. show that RNA G-quadruplexes can directly influence TDP-43 aggregation, condensation, localization, and toxicity across biochemical and cellular models. The study establishes G4 structure as a mechanistic variable in protein-misfolding research while defining important limits for translating G-quadruplex stabilization into neurodegeneration experiments.

• GW 4869: Exosome Workflow and Assay Guide

  2026-10-01

  GW 4869 combines neutral sphingomyelinase inhibition with a practical strategy for testing extracellular-vesicle communication. This guide translates lupus nephritis findings into controlled donor–recipient assays, formulation safeguards, and troubleshooting checkpoints.

• Ridaforolimus for mTOR and Senescence Assays

  2026-09-30

  Ridaforolimus, also called Deforolimus or MK-8669, gives researchers a concentration-controlled way to interrogate mTOR signaling, cancer-cell growth, VEGF production, and treatment response. Its value extends beyond a standard viability screen: paired pathway, apoptosis, and senescence measurements can distinguish cytostasis from cell death and help evaluate computationally prioritized assay designs.

• Copper–Hexetidine Synergy in Oral Streptococci

  2026-09-30

  Grytten, Scheie, and Giertsen showed that copper and hexetidine produced strong in vitro antibacterial synergy against Streptococcus sobrinus and Streptococcus sanguis. By combining broth-dilution MIC testing, fractional inhibitory concentration analysis, and growth curves, the study provided a practical framework for evaluating combination effects in oral microbiology.

• SMPD4, Ceramide, and Primary Cilia in Brain Development

  2026-09-29

  The 2024 Development study identifies SMPD4-dependent ceramide production as a mechanistic link between sphingolipid metabolism, primary cilium integrity, neural progenitor survival, and brain development. By combining a mouse model with SMPD4-deficient human induced pluripotent stem cells, the authors show that impaired ceramide production contributes to cerebellar hypoplasia and shortened primary cilia, with ciliary defects rescued by exogenous ceramide.

• Tunicamycin and Autophagy: Stress-to-Flux Assays

  2026-09-29

  Tunicamycin is more than an N-glycosylation inhibitor: it can help separate ER stress from downstream autophagy flux. This guide translates a plant VPS41 trafficking study into practical assay decisions while defining the limits of cross-system interpretation.

• GW 4869 in Exosome-Mediated Kidney Injury

  2026-09-28

  GW 4869 provides a practical pharmacological switch for testing whether extracellular vesicle signaling drives glomerular endothelial injury. This guide connects neutral sphingomyelinase inhibition with donor-cell pretreatment, exosome validation, HMGB1–TRIM27 assays, and troubleshooting controls for lupus nephritis models.

• Methoxy-X04 for Mapping Aβ Clearance in AD

  2026-09-28

  Explore how Methoxy-X04, a fluorescent amyloid beta probe, can help researchers map amyloid pathology in studies of rTMS and microglial activity. This article explains what plaque imaging can reveal—and what it cannot prove—when investigating Alzheimer’s disease mechanisms.

7976 records 1/532 page Next 12345 下5页 Last page